Work

Abiraterone acetate (AA) followed by randomization to dasatinib (D) or sunitinib malate (S) in metastatic castrate resistant prostate cancer (mCRPC)

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw372.11

Authors: E. Efstathiou, A. Tsikkinis, S. Wen, E. Li Ning Tapia, A. Hoang, A. Aparicio, S.-M. Tu, G. Rangel, P. Troncoso, P. Corn, J. Araujo, C. Logothetis

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2588116612

FWCI:

Cites:

Cited by: 1

Related to: 10